Jefferies: Data suggest Genmab drug could be a game-changer
Financing firm Jefferies believes abstracts for the upcoming ASH meeting in December confirm that Genmab and pharma partner Janssen could have a game-changer on their hands with blood cancer treatment Darzalex.
BY STEFAN SINGH KAILAY
Genmab is riding on a wave of success with its oncology medication Darzalex (daratumumab), on which it has partnered with US-based pharma company Janssen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
